MannKind reported $111.83M in Current Liabilities for its fiscal quarter ending in June of 2025.


Current Liabilities Change Date
Adma Biologics USD 74.94M 19.4M Jun/2025
Dynavax Technologies USD 118.23M 49.85M Jun/2025
Eli Lilly USD 39.02B 8.95B Jun/2025
Halozyme Therapeutics USD 134.28M 16.1M Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
MacroGenics USD 39M 16.53M Jun/2025
MannKind USD 111.83M 4.11M Jun/2025
Merck USD 26.04B 863M Jun/2025
Novo Nordisk DKK 236.12B 27.76B Mar/2025
Pfizer USD 37.73B 1.27B Jun/2025
Sanofi 29.06B 3.16B Jun/2025
Xencor USD 96.08M 7.65M Jun/2025